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دراسة فاعلية ميسوبروستول كعالج غري جراحي حلاالت اإلجهاض يف الثلث 
األول من احلمل
خربة املستشفى السلطاين، عمان
قمرية اأمبو�سعيدية و اأنيتا زت�سي
abstract: Objectives: Non-invasive methods of inducing a miscarriage are now considered an effective alternative 
to surgical evacuation (dilatation and curettage). This study aimed to evaluate the effectiveness of misoprostol in the 
termination of first-trimester miscarriages. Methods: This prospective study was conducted between October 2009 
and September 2010 and assessed all patients admitted to the Royal Hospital in Muscat, Oman, for the termination 
of first-trimester miscarriages during the study period. All patients received misoprostol and the rates of successful 
termination were measured. Patient satisfaction was assessed using a short questionnaire. Results: A total of 290 
women were included in the study. Termination with misoprostol was successful in 61.38% of the subjects. Of the 
remaining subjects requiring additional surgical evacuation (n = 112), 58.93% required evacuation due to failed 
termination with misoprostol and 65.18% underwent early evacuation (≤24 hours since their last misoprostol dose). 
The majority of patients experienced no side-effects due to misoprostol (89.66%). Pain was controlled with simple 
analgesics in 70.00% of the subjects. A high satisfaction rate (94.83%) with the misoprostol treatment was reported. 
Conclusion: Misoprostol was a well-tolerated drug which reduced the rate of surgical evacuation among the study 
subjects. This medication can therefore be used safely in the management of incomplete miscarriages.
Keywords: Misoprostol; First Trimester Pregnancy; Miscarriage; Incomplete Abortion; Dilation and Curettage; 
Oman.
امللخ�ص: الهدف: تعترب العالجات غري اجلراحية حلث الإجها�ض˗يف الوقت احلايل˗فعالة و بدائل ماأمونة للتفريغ اجلراحي. هدفت هذه 
)م�ستقبلية(  الطريقة: درا�سة ا�ستطالعية  الدرا�سة لتقييم فاعليةعقار املي�سوبرو�ستول لإنهاء احلمل˗الإجها�ض يف الثلث الأول من احلمل. 
يف الفرتة ما بني اأكتوبر 2009 و �سبتمرب 2010. �سمت الدرا�سة جميع املري�سات اللواتي مت قبولهن يف ق�سم اأمرا�ض الن�ساء يف امل�ست�سفى 
ال�سلطاين˗م�سقط، �سلطنة عمان˗لإنهاء الإجها�ض يف الثلث الأول من احلمل با�ستخدام اأقرا�ض املي�سوبرو�ستول. مت قيا�ض فاعلية العالج 
املي�سوبرو�ستول  الدرا�سة. جنح عقار  290 مري�سة يف  �ساركت  النتائج:  با�ستبيان ق�سري.  للعالج  كما مت تقييم م�ستوى قبول املري�سات 
%58.93 منهن ب�سبب  التفريغ اجلراحي،  112 حالة لعملية  الدرا�سة. خ�سعت  %61.38 من امل�ساركات يف  اإحداث الإجها�ض يف  كان يف 
ف�سل املي�سوبرو�ستول. وقد لوحظ اأن التفريغ اجلراحي قد مت خالل فرتة اأق�رس من 24 �ساعة من اأخذ اأقرا�ض املي�سوبرو�ستول يف 65.18% 
من احلالت. مل تكن هناك اأي م�ساعفات يف %89.66 من احلالت. مت ت�سكني الأمل ل %70.00 من احلالت مب�سكنات ب�سيطة. تقبلت معظم 
املري�سات العالج ب�سكل جيد. اخلال�صة: املي�سوبرو�ستول هو دواء جيد وي�ساعد على تقليل معدل عمليات التفريغ اجلراحي و ميكن ا�ستخدامه 
باأمان لعالج حالت الإجها�ض غري املكتمل.
مفتاح الكلمات: املي�سوبرو�ستول؛ الثلث الأول من احلمل؛ اإجهَا�ض؛ اإجها�ض غري مكتمل؛ تفريغ جراحي للرحم؛ عمان.
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Advances in Knowledge
- This study is the first in Oman to investigate the effectiveness of misoprostol in inducing first-trimester miscarriages. 
- Results from this study showed that the medication had minimal side-effects among the studied group of women.
Application to Patient Care 
- Surgical evacuations can result in complications that affect future obstetric outcomes, including cervical incompetence, uterine 
perforation, intrauterine adhesions and morbidly adherent placenta. Misoprostol is a non-invasive alternative to induce miscarriage 
and avoid these potential complications.
- Misoprostol is currently not available in all hospitals in Oman. The results of this study may help to encourage wider utilisation of this 
medication in inducing miscarriages.
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Miscarriage is defined as a pregnancy that ends spontaneously before the fetus is viable. The most common complication 
of early pregnancy is miscarriage; Robledo et al. 
estimated that approximately 8–20% of clinically 
recognised pregnancies under 20 gestational weeks 
end in miscarriage, with 80% occurring in the first 12 
gestational weeks.1 Three options exist for managing 
a miscarriage in a patient: expectant management, 
surgical evacuation or medical/pharmaceutical 
management. While surgical evacuation is a fast and 
effective procedure when performed by a well-trained 
physician, it is nevertheless a blind and invasive 
procedure that carries a risk of injury, bleeding and 
infection, in addition to possible complications from 
the anaesthesia. Medical methods for the induction of 
miscarriage are now considered an effective alternative 
to surgical evacuation. Prostaglandin analogues, of 
which misoprostol is the most common, are widely 
utilised in several countries. In 2009, 40%, 72% and 
76% of abortions were induced via medication in the 
UK, Sweden and Finland, respectively.2
Misoprostol is a synthetic prostaglandin E1 
analogue which causes uterine contractions and 
softening and dilation of the cervix. It has been used off-
label in the management of miscarriage, postpartum 
haemorrhage, induction of labour and ripening of the 
cervix.3 Although misoprostol is not yet licensed by 
the Food and Drug Administration in the USA for the 
above indications, pregnancy was removed from the 
list of absolute contraindications to misoprostol use 
in 2002.4 The advantages of misoprostol include its 
low cost, long shelf life, lack of need for refrigeration 
and worldwide availability.3 The aim of this study was 
to evaluate the success of misoprostol as an agent for 
medical termination in first-trimester miscarriages at 
the Royal Hospital, Muscat, Oman.
Methods
This prospective study was conducted between 
October 2009 and September 2010 and included 
all patients admitted for the termination of a first-
trimester miscarriage to the Gynaecology Ward at the 
Royal Hospital during the study period. The exclusion 
criteria were termination of a viable pregnancy and 
absolute contraindications for misoprostol, including 
patients with a suspected or confirmed ectopic 
pregnancy, gestational trophoblastic diseases, a high 
risk of uterine rupture, an intrauterine device in 
situ, an allergy to prostaglandins or haemodynamic 
instability. Women who underwent a medical termi- 
nation of pregnancy for maternal or fetal indications 
were excluded from the study and only those with a 
diagnosis of an incomplete or missed/silent miscarriage 
were included. All subjects underwent a thorough 
physical examination. Baseline characteristics, inclu- 
ding age, parity, gestational age and type of mis-
carriage, were obtained. A complete blood count 
was performed to assess pre-treatment haemoglobin 
levels in all candidates, in addition to blood grouping. 
Rhesus typing and antibody screening tests were 
also performed. 
All of the subjects were given misoprostol accor-
ding to hospital protocol. Patients with incomplete 
miscarriages received a single oral dose of 600 µg of 
misoprostol. Those with missed miscarriages received 
vaginal misoprostol with a maximum of three doses 
of 800 µg every 24 hours. Vaginal misoprostol was 
avoided for patients with vaginal bleeding or leaking 
and for those with a high white blood cell count. In 
such cases, the same dose was given orally. For 
patients with previous uterine scarring, a half dose 
of misoprostol was given. All of the subjects were 
admitted as inpatients to monitor bleeding and the 
development of any side-effects. Patients’ analgaesia 
requirements were also recorded. All patients 
with Rhesus-negative blood were given an anti-D 
immunoglobulin injection before discharge.
The complete miscarriage rate was determined 
to assess the efficacy of misoprostol. Complete 
miscarriages were defined as successful cases 
that did not require surgical evacuation after the 
administration of misoprostol. Ultrasonography was 
performed on each patient to confirm that no products 
of conception remained. Diagnosis of a complete 
miscarriage was based on the clinical judgment of 
the attending obstetrician. However, an endometrial 
thickness of 14 mm was considered to be the cut-off 
value for a complete miscarriage. Retained products 
of conception indicated the need for a surgical 
evacuation. The time interval between the last dose of 
misoprostol and surgical evacuation was also assessed. 
Following the completion of their treatment with 
misoprostol, patient satisfaction was determined using 
a short questionnaire. Responses to the following two 
questions were recorded: “Are you satisfied with the 
treatment?” and “If you have a similar problem in the 
future, are you going to use misoprostol again?”. 
Data were analysed using the Statistical Package for 
the Social Sciences (SPSS), Version 17.0 (IBM Corp., 
Chicago, Illinois, USA). This study was approved by 
the Medical Ethics & Scientific Research Committee 
of the Royal Hospital (MESRC #37). All patients 
gave informed verbal consent prior to their inclusion 
in the study.
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Results
A total of 290 women with first-trimester miscarriages 
were admitted to the Royal Hospital during the study 
period. The mean age was 32.9 years and mean parity 
was 2.6. The majority of the subjects were admitted 
due to a diagnosis of incomplete miscarriage (63.45%). 
Fetal age ranged from 5–12 gestational weeks with a 
mean age of 9.4 gestational weeks. The overall rate of 
complete termination with misoprostol was 61.38%, 
while 38.62% of cases required further surgical 
evacuation. 
A total of 112 patients underwent surgical 
evacuation. The indications for surgical evacuation 
are shown in Figure 1. The vast majority of patients 
discontinued misoprostol and underwent evacuation 
because of failed termination with the drug 
(58.93%). The second most common indication was 
bleeding (19.64%), although seven patients only had 
postevacuation haemoglobin levels for comparison. 
Four patients experienced a significant drop in 
haemoglobin levels (>2.0 g/dL). However, only one 
patient required a blood transfusion. The mean drop 
in haemoglobin level was 2.2 g/dL [Figure 2]. Surgical 
evacuation was carried out for 19 patients who refused 
to continue the misoprostol treatment. Three patients 
underwent a surgical evacuation due to fever and one 
patient due to a suspected septic abortion indicated by 
foul smelling discharge, although a subsequent culture 
was negative for infection. The distribution of patients 
undergoing surgical evacuation by miscarriage type is 
shown in Figure 3.
Early surgical evacuations (within 24 hours of the 
last dose of misoprostol) were performed for 65.18% 
of the subjects. After excluding cases with bleeding 
and suspected infection, 44.64% of the women 
who underwent a surgical evacuation due to failed 
termination did so within 24 hours of receiving their 
last dose of misoprostol. Only 10.71% of the patients 
underwent surgical evacuation after 72 hours [Figure 4].
The majority of patients experienced no side-effects 
from misoprostol (89.66%). The remaining women 
had the following side-effects: bleeding (7.59%), fever 
(2.41%) and chills (0.34%). All patients with significant 
bleeding based on the subjective assessment of the 
attending doctor underwent surgical evacuation. 
All of the febrile women had fevers which subsided 
 
Figure 1: Indications leading to surgical evacuation 
after the use of misoprostol among patients admitted 
for the termination of first-trimester miscarriages 
(N = 112).
 
Figure 3: Distribution of patients undergoing suction 
evacuation according to their miscarriage diagnosis 
among patients admitted for the termination of first-
trimester miscarriages (N = 112).
 
Figure 2: Haemoglobin levels pre- and post-treatment with 
misoprostol among patients admitted for the termination 
of first-trimester miscarriages and who underwent suction 
evacuation for heavy vaginal bleeding (N = 7).
Hb = haemoglobin.
 
Figure 4: Time interval between the last dose of 
misoprostol and surgical evacuation among patients 
admitted for the termination of first-trimester 
miscarriages and requiring evacuation (N = 112). 
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within 24 hours. None of the patients experienced 
any gastrointestinal side-effects. Only one patient 
experienced prolonged bleeding lasting for four weeks 
after management with misoprostol; she underwent 
a surgical evacuation and subsequent histopathology 
showed only blood clots with no retained products of 
conception.
Analgaesics were offered to all of the patients, 
but the majority tolerated the pain well. Pain was 
controlled with paracetamol and non-steroidal anti-
inflammatory drugs (NSAIDs) such as mefenamic 
acid, diclofenac sodium tablets or intramuscular 
injections in 70.00% of patients. Of the remaining 
patients, 26.55% did not require analgesia, while 3.45% 
received tramadol due to NSAID allergies. 
In terms of patient satisfaction, 277 subjects (95.52%) 
said they were satisfied with misoprostol. Of these, 275 
indicated that they would use it again. Despite their 
satisfaction, the remaining two patients stated that they 
would not undergo misoprostol treatment a second 
time due to the longer hospital stay required. Of the 13 
patients who were not satisfied with misoprostol, two 
nevertheless stated that they would try it again in the 
future in order to avoid the potential complications of a 
surgical evacuation [Table 1]. 
Discussion
During their reproductive years, 25.00% of all women 
will experience at least one early pregnancy miscar-
riage.1 Suction evacuation is the usual treatment for 
miscarriage, regardless of gestational age. In three 
small randomised controlled trials, expectant manage-
ment showed a success rate of 79.00% in three days 
for incomplete miscarriages and only 37.00% in seven 
days for silent miscarriages.5 There were no differences 
in complication rates.5 
Studies have suggested that pregnancy termination 
efficacy may be higher among early pregnancies (six 
gestational weeks). Faúndes et al. determined that the 
rate of effectiveness for misoprostol in first-trimester 
pregnancy terminations was 85.00%.6 Davis et al. also 
reported a success rate of 85.00% for misoprostol.7 
However, they noted that post-treatment bleeding 
occurred for longer periods of time with misoprostol, 
although none of the patients required a blood 
transfusion.7 The duration of post-treatment bleeding 
was difficult to assess in the current study as most cases 
were straightforward and were therefore followed-up 
by local general practitioners outside of the Royal 
Hospital. Chen et al. reported that nearly 30.00% of 
deliveries in the USA were performed via Caesarean 
section;8 it is therefore not surprising that many 
women who suffer from miscarriages also have a 
history of uterine surgery. Misoprostol may be a 
preferable option for these patients. In the present 
study, there were no cases of uterine rupture or 
adverse outcomes. 
Misoprostol can be administered at different doses 
and through different routes (vaginal, oral, sublingual 
or rectal). A Cochrane review of 19 randomised 
controlled trials indicated that the vaginal route is 
the best option, with no significant difference in side-
effects.9 Vaginal misoprostol administration results 
in slower absorption of the drug and longer duration 
of stimulation in comparison to oral administration. 
The sublingual route avoids the first-pass effect and 
is associated with more rapid absorption and higher 
peak levels than those obtained with other routes.9 
Misoprostol is usually administered vaginally in three 
doses of 800 µg each; this regimen has been found to 
yield a success rate of 90.00% in the first trimester, 
with 80.00% and 95.00% of patients expelling the 
products of conception within 24 and 48 hours of 
the dose, respectively.5 The same treatment plan was 
used in the current study but had lower success rates 
due to early intervention with surgical evacuation. 
It should be noted that the majority of patients who 
underwent a surgical evacuation in the current study 
did so within 48 hours of their last misoprostol dose. 
The efficacy of misoprostol is related to the dosage as 
a lower dose will have a weaker effect. However, the 
rate of side-effects does not seem to be related to the 
dosage. While sublingual misoprostol has a similar 
efficacy to vaginal misoprostol, Gemzell-Danielsson 
et al. observed that this route was associated with 
more frequent side-effects (e.g. diarrhoea).10
Different factors may have influenced the 
decision for surgical evacuation in the current study. 
Importantly, misoprostol was restricted to inpatient 
use only and there was pressure from both the patients 
and hospital administration to shorten hospital stays, 
increase patient turnover and reduced patient overflow 
and bed shortages. Early interventions in first trimester 
miscarriages could be minimised by the initiation of 
misoprostol as an outpatient treatment. Additionally, 
Table 1: Patient satisfaction with the use of misoprostol 
among patients admitted for the termination of first-
trimester miscarriages (N = 290)
Willingness to try 






No 11 2 13
Yes 2 275 277
Total 13 277 290
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delaying the assessment of misoprostol efficacy until 
a week after the last dose is recommended. However, 
more studies on this topic are needed.
Side-effects of misoprostol are usually transient 
and self-limiting. The most commonly reported 
side-effect is vaginal bleeding, which can last for 
2–6 weeks. Faúndes et al. reported a mean drop 
in haemoglobin levels of 0.2–1.0 g/dL for patients 
receiving misoprostol, although blood transfusions 
were rarely necessary.6 In the current study, the 
mean drop in haemoglobin was significant, with one 
patient requiring a blood transfusion. There is no clear 
reason for this discrepancy; however, pre-existing 
iron deficiencies and anaemia may have contributed 
to the low haemoglobin levels detected. Abdominal 
cramping beginning as early as 30 minutes after 
administration of the drug is another common side-
effect of misoprostol.6 For this reason, most patients in 
the present study were given analgesics and NSAIDs 
concurrently with misoprostol. 
There is no consensus regarding the use of 
antibiotics during treatment of miscarriage. Although 
research has shown that the infection rate is lower after 
a medical/pharmaceutical induction of miscarriage, 
it is important to note that antibiotics are more 
commonly used after pharmaceutical inductions 
rather than surgical evacuations.6 In this study, the 
decision to use post-procedure antibiotics was left to 
the treating physician.
Patient satisfaction is a useful measure to 
determine the efficacy of any treatment and assess 
the quality of healthcare provision. Additionally, 
patient satisfaction rates indicate acceptance of a 
treatment. In the present study, two direct close-ended 
questions were used to assess satisfaction among the 
subjects. However, general patient satisfaction was 
not assessed beyond the acceptance of misoprostol 
as an alternative to surgical evacuation. Ideally, 
patients should be surveyed regarding a wide range 
of factors associated with their treatment, including 
inpatient care, experience with misoprostol, route of 
misoprostol administration, type of analgesia received 
and patient-provider relationship. The current study is 
also limited as a more precise satisfaction rate could 
have been determined by analysing women who had 
had previous surgical evacuations and comparing 
them with women receiving pharmaceutical treatment 
for a current miscarriage. 
Conclusion
Misoprostol was an effective treatment for the 
management of first-trimester miscarriages in the 
studied group. The administration of misoprostol 
significantly reduced the surgical evacuation rate 
with minimal side-effects. Subjects reported high 
rates of satisfaction and acceptance with misoprostol. 
Therefore, misoprostol is recommended as a safe 
drug for use among outpatients with incomplete 
miscarriages as an alternative to surgical evacuation.  
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